Patients who had stem cells harvested or received a stem cell transplant or both
| Patient . | CD34 collected, agent 1 (agent 2), CD34+/kg . | Time to platelet recovery, d, untransfused 20 000/mm3 . | Time to ANC recovery, d, 1500/mm3 . | Mobilization regimen 1 (regimen 2) . | Infused CD34+ × 106/1000 (adjusted for post-thaw washing and recovery) . |
|---|---|---|---|---|---|
| 4 | 10.65 | 12 | 9 | Cyclophosphamide + G-CSF | 5.9 (5.33) |
| 6 | 14.41 | 24 | 13 | Bortezomib/cyclophosphamide + G-CSF | 6.63 (6.09) |
| 7 | 59.97 | 13 | 10 | Cyclophosphamide + G-CSF | 10.43 (6.2) |
| 9 | 50 | 13 | 11 | Bortezomib/cyclophosphamide + G-CSF | 12.38 (11.85) |
| 10 | 3.1 (5.7) | 11 | 15 | AMD (cyclophosphamide + G-CSF) | 3.1 (NA) |
| 13 | 15.82 | 15 | 10 | Cyclophosphamide + G-CSF | 6.57 (6.33) |
| 16* | 9.5 | GF | GF | Cyclophosphamide + G-CSF | 6.00 + 3.5 |
| 18 | 4.93 | 15 | 9 | Cyclophosphamide + G-CSF | 5.09 (4.06) |
| 19 | 19.05 | 15 | 10 | Bortezomib/cyclophosphamide + G-CSF | 9 (8.86) |
| 22 | 9.53 | 18 | 11 | Bortezomib/cyclophosphamide + G-CSF | 4.01 (3.38) |
| 23 | 47.48 | 14 | 13 | Bortezomib/cyclophosphamide + G-CSF | 7.15 (6.95) |
| 24 | 38.7 | 21 | 11 | Bortezomib/cyclophosphamide + G-CSF | 9.18 (8.43) |
| 25 | 50.78 | 21 | 13 | Bortezomib/cyclophosphamide + G-CSF | 8.70 (7.79) |
| 32 | 236.31 | 17 | 10 | Bortezomib/cyclophosphamide + G-CSF | 21.56 (17.74) |
| 33 | 10.6 | 15 | 11 | Cyclophosphamide + G-CSF | 4.5 (4.27) |
| 35 | 13.07 | Not indicated (platelet sustained >20 000) | 9 | Cyclophosphamide + G-CSF | 6.15 (5.67) |
| 53 | 13.88 | 17 | 12 | Cyclophosphamide + G-CSF | 5.07 (4.92) |
| 63 | 21.38 | 16 | 13 | Bortezomib/cyclophosphamide + G-CSF | 9.35 (8.63) |
| Patient . | CD34 collected, agent 1 (agent 2), CD34+/kg . | Time to platelet recovery, d, untransfused 20 000/mm3 . | Time to ANC recovery, d, 1500/mm3 . | Mobilization regimen 1 (regimen 2) . | Infused CD34+ × 106/1000 (adjusted for post-thaw washing and recovery) . |
|---|---|---|---|---|---|
| 4 | 10.65 | 12 | 9 | Cyclophosphamide + G-CSF | 5.9 (5.33) |
| 6 | 14.41 | 24 | 13 | Bortezomib/cyclophosphamide + G-CSF | 6.63 (6.09) |
| 7 | 59.97 | 13 | 10 | Cyclophosphamide + G-CSF | 10.43 (6.2) |
| 9 | 50 | 13 | 11 | Bortezomib/cyclophosphamide + G-CSF | 12.38 (11.85) |
| 10 | 3.1 (5.7) | 11 | 15 | AMD (cyclophosphamide + G-CSF) | 3.1 (NA) |
| 13 | 15.82 | 15 | 10 | Cyclophosphamide + G-CSF | 6.57 (6.33) |
| 16* | 9.5 | GF | GF | Cyclophosphamide + G-CSF | 6.00 + 3.5 |
| 18 | 4.93 | 15 | 9 | Cyclophosphamide + G-CSF | 5.09 (4.06) |
| 19 | 19.05 | 15 | 10 | Bortezomib/cyclophosphamide + G-CSF | 9 (8.86) |
| 22 | 9.53 | 18 | 11 | Bortezomib/cyclophosphamide + G-CSF | 4.01 (3.38) |
| 23 | 47.48 | 14 | 13 | Bortezomib/cyclophosphamide + G-CSF | 7.15 (6.95) |
| 24 | 38.7 | 21 | 11 | Bortezomib/cyclophosphamide + G-CSF | 9.18 (8.43) |
| 25 | 50.78 | 21 | 13 | Bortezomib/cyclophosphamide + G-CSF | 8.70 (7.79) |
| 32 | 236.31 | 17 | 10 | Bortezomib/cyclophosphamide + G-CSF | 21.56 (17.74) |
| 33 | 10.6 | 15 | 11 | Cyclophosphamide + G-CSF | 4.5 (4.27) |
| 35 | 13.07 | Not indicated (platelet sustained >20 000) | 9 | Cyclophosphamide + G-CSF | 6.15 (5.67) |
| 53 | 13.88 | 17 | 12 | Cyclophosphamide + G-CSF | 5.07 (4.92) |
| 63 | 21.38 | 16 | 13 | Bortezomib/cyclophosphamide + G-CSF | 9.35 (8.63) |
ANC indicates absolute neutrophil count; G-CSF, granulocyte colony-stimulating factor; GF, graft failure; and NA, not available.
Patient 16 died of transplantion-related complications.